CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-27..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-27..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-27..
Borrowing debt
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 5.46M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 7.53B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | (m) | (m) | $5.46M | (m) | (m) | (m) | $7.53B | (m) |
| 2026-03-28 | (m) | (m) | $6.70M | (m) | (m) | (m) | $7.73B | (m) |
| 2025-12-27 | (m) | (m) | $166.00K | (m) | (m) | (m) | $7.14B | (m) |
| 2025-09-27 | (m) | (m) | $54.00K | (m) | (m) | (m) | $7.51B | (m) |
| 2025-06-28 | (m) | (m) | $98.00K | (m) | (m) | (m) | $7.56B | (m) |
| 2025-03-29 | (m) | (m) | $121.00K | (m) | (m) | (m) | $7.58B | (m) |
| 2024-12-28 | (m) | (m) | $155.00K | (m) | (m) | (m) | $7.53B | (m) |
| 2024-09-28 | (m) | (m) | $157.00K | (m) | (m) | (m) | $8.00B | (m) |
| 2024-06-29 | (m) | (m) | $435.00K | (m) | (m) | (m) | $7.95B | (m) |
| 2024-03-30 | (m) | (m) | $459.00K | (m) | (m) | (m) | $8.15B | (m) |
| 2023-12-30 | (m) | (m) | $3.17M | (m) | (m) | (m) | $8.20B | (m) |
| 2023-09-30 | (m) | (m) | $797.00K | (m) | (m) | (m) | $7.61B | (m) |
| 2023-07-01 | (m) | (m) | $1.19M | (m) | (m) | (m) | $7.77B | (m) |
| 2023-04-01 | (m) | (m) | $4.00M | (m) | (m) | (m) | $7.70B | (m) |
| 2022-12-31 | (m) | (m) | $1.35M | (m) | (m) | (m) | $7.60B | (m) |
| 2022-09-24 | (m) | (m) | $0.00 | (m) | (m) | (m) | $7.38B | (m) |
| 2022-06-25 | (m) | (m) | $95.00K | (m) | (m) | (m) | $7.53B | (m) |
| 2022-03-26 | (m) | (m) | $99.00K | (m) | (m) | (m) | $7.08B | (m) |
| 2021-12-25 | (m) | (m) | $101.00K | (m) | (m) | (m) | $7.02B | (m) |
| 2021-09-25 | (m) | (m) | $105.00K | (m) | (m) | (m) | $7.06B | (m) |
| 2021-06-26 | (m) | (m) | $108.00K | (m) | (m) | (m) | $6.72B | (m) |
| 2021-03-27 | (m) | (m) | $109.00K | (m) | (m) | (m) | $5.81B | (m) |
| 2020-12-26 | (m) | (m) | $47.20M | (m) | (m) | (m) | $5.49B | (m) |
| 2020-09-26 | (m) | (m) | $45.02M | (m) | (m) | (m) | $5.21B | (m) |
| 2020-06-27 | (m) | (m) | $50.51M | (m) | (m) | (m) | $5.24B | (m) |
| 2020-03-28 | (m) | (m) | $44.74M | (m) | (m) | (m) | $5.20B | (m) |
| 2019-12-28 | (m) | (m) | $35.55M | (m) | (m) | (m) | $4.69B | (m) |
| 2019-09-28 | (m) | (m) | $30.61M | (m) | (m) | (m) | $4.58B | (m) |
| 2019-06-29 | (m) | (m) | $30.71M | (m) | (m) | (m) | $4.63B | (m) |
| 2019-03-30 | (m) | (m) | $28.23M | (m) | (m) | (m) | $3.93B | (m) |
| 2018-12-29 | (m) | (m) | $28.23M | $1.63B | (m) | (m) | $3.86B | (m) |
| 2018-09-29 | (m) | (m) | $28.23M | $1.64B | (m) | (m) | $3.80B | (m) |
| 2018-06-30 | (m) | (m) | $28.23M | $1.79B | (m) | (m) | $3.87B | (m) |
| 2018-03-31 | (m) | (m) | $111.00K | $1.11B | (m) | (m) | $3.00B | (m) |
| 2017-12-30 | (m) | (m) | $28.55M | $1.09B | (m) | (m) | $2.93B | (m) |
| 2017-09-30 | (m) | (m) | $24.48M | $1.13B | (m) | (m) | $2.87B | (m) |
| 2017-07-01 | (m) | (m) | $24.58M | $1.09B | (m) | (m) | $2.77B | (m) |
| 2017-04-01 | (m) | (m) | $24.56M | $1.15B | (m) | (m) | $2.70B | (m) |
| 2016-12-31 | (m) | (m) | $24.56M | $1.19B | (m) | (m) | $2.71B | (m) |
| 2016-09-24 | (m) | (m) | $24.57M | $1.21B | (m) | (m) | $2.69B | (m) |
| 2016-06-25 | (m) | (m) | $32.70M | $1.31B | (m) | (m) | $2.76B | (m) |
| 2016-03-26 | (m) | (m) | $20.20M | $817.74M | (m) | (m) | $2.10B | (m) |
| 2015-12-26 | (m) | (m) | $15.19M | $821.04M | (m) | (m) | $2.07B | (m) |
| 2015-09-26 | (m) | (m) | $15.20M | $809.87M | (m) | (m) | $2.03B | (m) |
| 2015-06-27 | (m) | (m) | $15.20M | $727.89M | (m) | (m) | $1.89B | (m) |
| 2015-03-28 | (m) | (m) | $31.70M | $728.44M | (m) | (m) | $1.85B | (m) |
| 2014-12-27 | (m) | (m) | $31.71M | $722.04M | (m) | (m) | $1.89B | (m) |
| 2014-09-27 | (m) | (m) | $31.72M | $737.91M | (m) | (m) | $1.84B | (m) |
| 2014-06-28 | (m) | (m) | $31.74M | $771.06M | (m) | $128.87M | $1.86B | (m) |
| 2014-03-29 | (m) | (m) | $26.49M | $613.60M | (m) | $181.30M | $1.65B | (m) |
| 2013-12-28 | (m) | (m) | $21.24M | $641.81M | (m) | (m) | $1.64B | (m) |
| 2013-09-28 | (m) | (m) | $15.99M | $623.75M | (m) | $141.54M | $1.64B | (m) |
| 2013-06-29 | (m) | (m) | $15.98M | $619.25M | (m) | $120.45M | $1.62B | (m) |
| 2013-03-30 | (m) | (m) | $130.66M | $517.51M | (m) | $107.27M | $1.60B | (m) |
| 2012-12-29 | (m) | (m) | $-139.37M | $527.08M | (m) | $116.47M | $1.59B | (m) |
| 2012-09-29 | (m) | (m) | $125.59M | $543.14M | (m) | $89.58M | $1.57B | (m) |
| 2012-06-30 | (m) | (m) | $134.81M | $551.39M | (m) | $82.70M | $1.55B | (m) |
| 2012-03-31 | (m) | (m) | $29.55M | $674.74M | (m) | $67.17M | $1.56B | (m) |
| 2011-12-31 | (m) | (m) | $14.73M | $703.17M | (m) | $74.26M | $1.56B | (m) |
| 2010-12-25 | (m) | (m) | $30.54M | $670.22M | (m) | $188.99M | $1.73B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |